Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
04/2003
04/17/2003WO2003030910A1 Pharmaceutical composition for the treatment of disorders of non-human mammals
04/17/2003WO2003030909A1 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
04/17/2003WO2003030908A2 Inhibitors of the egf receptor for the treatment of thyroid cancer
04/17/2003WO2003030905A1 Dihydroorotate dehydrogenase inhibitor
04/17/2003WO2003030902A1 Imidazole derivates as anti-inflammatory agents
04/17/2003WO2003030897A1 Pyrrolidinone derivatives
04/17/2003WO2003030891A1 Use of hydroxyoleic acid and similar compounds in the production of medicaments
04/17/2003WO2003030890A1 Immune system activators
04/17/2003WO2003030884A2 Use of solasonine for the treatment of skin tumors
04/17/2003WO2003030876A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process
04/17/2003WO2003030833A2 Angiopoietin-2 specific binding agents
04/17/2003WO2003030824A2 Methods and compositions for treating dermal lesions
04/17/2003WO2003030819A2 Tetracycline derivatives and methods of use thereof
04/17/2003WO2003030814A2 Cross-regulin composition of turmeric-derived tetrahydrocurcuminoids for skin lightening and protection against uvb rays
04/17/2003WO2003030616A2 21132, a human g-protein coupled receptor family member and uses therefor
04/17/2003WO2003020259A3 Combinations of dmxaa and other anti-cancer agents
04/17/2003WO2003013591A3 Pharmaceutical composition containing caspase-8 and/or caspase-9 useful for overcoming glucocorticoid- and cancer therapy-induced apoptosis resistance of tumours
04/17/2003WO2003013484A3 N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
04/17/2003WO2003011293A3 Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists
04/17/2003WO2003008457A3 Polysaccharidic esters of retinoic acid
04/17/2003WO2003005999A3 Methods of treating cytokine mediated diseases
04/17/2003WO2002098852A3 Novel benzothienyl or indole derivatives, and use thereof as inhibitors of prenyl transferase proteins
04/17/2003WO2002096903A3 Chemical derivatives and the use thereof as an anti-telomerase agent
04/17/2003WO2002094863A3 INTERFERON-α INDUCED GENE
04/17/2003WO2002094325A3 Cytotoxic cd44 antibody immunoconjugates
04/17/2003WO2002083727A3 Nucleic acid sequences of hyperplasies and tumors of the thyroid
04/17/2003WO2002078620A3 Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
04/17/2003WO2002076486A3 Histidine-rich glycoprotein
04/17/2003WO2002072636A3 Crystals of whole antibodies and fragments thereof and methods for making and using them
04/17/2003WO2002058694A9 Method of treating hematologic tumors and cancers using beta lapachone
04/17/2003WO2002058684A3 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
04/17/2003WO2002050289A9 Methods for the production of multimeric proteins, and related compositions
04/17/2003WO2002050284A3 Oxidoreductases
04/17/2003WO2002032865A1 Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds
04/17/2003WO2002032415A3 Process of making and method of use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa cells
04/17/2003WO2002029036A3 Lipid metabolism enzymes
04/17/2003WO2002024891A3 B7-like molecules and uses thereof
04/17/2003WO2002021134A3 Methods of diagnosing breast cancer and screening for modulators
04/17/2003WO2002020619A9 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
04/17/2003WO2002018576A3 Compositions and methods relating to lung specific genes
04/17/2003WO2002018575A3 Genes expressed in the cell cycle
04/17/2003WO2002018445A3 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
04/17/2003WO2002012341A3 Her-2/neu fusion proteins
04/17/2003WO2002010402A3 Isolation of drosophila and human polynucleotides encoding par-1 kinase, polypeptides encoded by the polynucleotides and methods utilizing the polynucleotides and polypeptides
04/17/2003WO2002004511A3 CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORS
04/17/2003WO2001094341A9 Quinazoline derivatives for the treatment of tumours
04/17/2003WO2001089494A8 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases
04/17/2003WO2001085210A3 Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
04/17/2003WO2001078709A3 Treatment of neurodegenerative disease
04/17/2003WO2001074402A3 Camptothecin conjugates
04/17/2003WO1999064401A3 Imidazolyl derivatives and their use as somatostatin receptor ligands
04/17/2003WO1998004278A3 Tetrapeptide derivatives of dolastatin as antitumor agents
04/17/2003WO1998003519A3 New bis-platinum complexes with polyamine ligands as antitumor agents
04/17/2003WO1998003518A3 New bis-platinum complexes with polymethylene derivatives as ligands having antitumor activity
04/17/2003US20030073857 26,27-Homologated-20-epi-2-alkyl-19-nor-vitamin D compounds
04/17/2003US20030073852 Anticancer agents
04/17/2003US20030073845 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
04/17/2003US20030073841 New benzo [b] pyrano [3,2-h] acridin-7-one compounds
04/17/2003US20030073837 Anticancer agents
04/17/2003US20030073745 Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
04/17/2003US20030073734 Condensation derivatives of thiocolchicine and baccatin as antitumor agents
04/17/2003US20030073732 Antiinflammatory agents
04/17/2003US20030073731 Alkylation therapy; anticancer agent
04/17/2003US20030073723 Antiinflammatory agents; rheumatic diseases; antiallergens
04/17/2003US20030073719 Chiral salt resolution
04/17/2003US20030073718 Enzyme inhibitors; cardiovascular disorders; antiinflammatory agents; autoimmune disease
04/17/2003US20030073707 Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease
04/17/2003US20030073704 Analgesics; antidiabetic agents; antiinflamamtory agents
04/17/2003US20030073698 Nitrogen-based camptothecin derivatives
04/17/2003US20030073693 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
04/17/2003US20030073692 Anticancer agents; viricides; Alzheimer's diseases
04/17/2003US20030073691 Antitumor agents; anticancer agents
04/17/2003US20030073686 Anticarcinogenic agents
04/17/2003US20030073685 Nitric oxide synthase inhibitor; antiinflammatory agents
04/17/2003US20030073684 Respiratory system disorders; cardiovascular disorders; hemorrhage therapy
04/17/2003US20030073682 Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
04/17/2003US20030073678 Vanadium compounds for treating cancer
04/17/2003US20030073677 Synergistic mixtures; anticancer agents; 2-(2 -methyl-4-thiazolyl)ethenyl)-4,17-dioxabicyclo(14.1.0)heptadecane-5,9 -dione or 4-aza-17-oxabicyclo(14.1.0) heptadecane-5,9-dione or 1-aza-13-cyclohexadecene-2,6-dione or 1-oxa-13-cyclohexadecene-2,6-dione derivatives
04/17/2003US20030073673 Hormonal contraceptive product
04/17/2003US20030073671 Side effect reduction; hormone replacement therapy
04/17/2003US20030073669 N-heterocyclic derivatives as NOS inhibitors
04/17/2003US20030073660 Anticancer agents; blood disorders
04/17/2003US20030073656 Using a tyrosine kinase receptor inhibitor
04/17/2003US20030073628 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
04/17/2003US20030073620 Genetic engineering; antibody binding to nucleic acid; disease therapy
04/17/2003US20030073611 Detoxification of cells, tissues
04/17/2003US20030073218 Enzyme inhibitor for us in the treatment and prevention of tumors
04/17/2003US20030073167 DNA encoding SNORF36 receptors
04/17/2003US20030073148 Antibodies binding to human airway trypsin-like protease and methods for utilizing the same
04/17/2003US20030073141 Monoclonal antibodies against a complex of human ACT and a serine protease
04/17/2003US20030073123 Detection of modulators of gene transcription inhibition; obtain sample of cells, incubate with modulator, monitor transcription pattern, compare to control, evaluate for transcription inhibition
04/17/2003US20030073118 MID 9002, a human sulfatase family member and uses therefor
04/17/2003US20030073080 Genetically engineered viral nucleotide sequences for use as tool in gene therapy and vaccine development
04/17/2003US20030073076 Analyzing modulators or treatments of fibroproliferative diseases; obtain sample, incubate with modulator, monitor marker expression, decreased expression indicate effective modulator
04/17/2003US20030072796 For activating T lymphocytes in vitro for the treatment of disease conditions
04/17/2003US20030072767 Compositions and methods for WT1 specific immunotherapy
04/17/2003US20030072764 Mucosal boosting following parenteral priming
04/17/2003US20030072763 Absorb in the low- energy, ultraviolet, visible, or near-infrared (NIR) region of the electromagnetic spectrum that are used for the phototherapy of tumors and other lesions
04/17/2003US20030072762 For enhancing Fc receptor-mediated antigen presentation, vaccines
04/17/2003US20030072759 Administering to a patient afflicted with a gastrointestinal tumor, a murine monoclonal antibody which specifically binds to an epitope of 17-1A antigen, the antibody being administered parenterally in multiple doses
1 ... 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 ... 2211